IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13850

Minehiko Inomata, Naoki Takata, Zenta Seto, Nozomu Murayama, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui

{"title":"Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio.","authors":"Minehiko Inomata, Naoki Takata, Zenta Seto, Nozomu Murayama, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui","doi":"10.21873/invivo.13850","DOIUrl":"10.21873/invivo.13850","url":null,"abstract":"Background/aim: Chemoimmunotherapy has improved overall survival in patients with extensive small-cell lung cancer (SCLC). However, the backgrounds of patients enrolled in clinical trials tend to differ from those of patients treated in clinical practice, and the effectiveness of chemoimmunotherapy may be unclear in some populations, including patients with poor performance status. This study aimed to evaluate the effectiveness of chemoimmunotherapy for SCLC patients in clinical practice while focusing on several subgroups.Patients and methods: We retrospectively analyzed the data of SCLC patients who received chemoimmunotherapy or chemotherapy. The association between chemoimmunotherapy and overall survival was evaluated by adjusting for patient backgrounds using the Cox proportional hazards model, followed by a subset analysis.Results: The chemoimmunotherapy and chemotherapy groups included 43 and 71 patients, respectively. The Cox proportional hazards model showed that chemoimmunotherapy was significantly associated with improved overall survival (hazard ratio=0.47, 95% confidential interval=0.26-0.83). Furthermore, subgroup analysis showed that overall survival was significantly improved in patients with good performance status, lower neutrophil/lymphocyte ratio, and no liver metastases. However, overall survival with chemoimmunotherapy was similar to that with chemotherapy and was less than 12 months in patients with a poor performance status or higher neutrophil/lymphocyte ratio.Conclusion: Chemoimmunotherapy was significantly associated with improved overall survival in clinical practice. However, the effectiveness was equivocal in SCLC patients with a poor performance status or higher neutrophil/lymphocyte ratio.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"467-472"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma. 上皮生长因子受体对犬软组织肉瘤中PI3K/AKT通路失调的潜在贡献。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13808

Alfarisa Nururrozi, Masaya Igase, Kyohei Miyanishi, Masashi Sakurai, Yusuke Sakai, Mika Tanabe, Takuya Mizuno

{"title":"Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma.","authors":"Alfarisa Nururrozi, Masaya Igase, Kyohei Miyanishi, Masashi Sakurai, Yusuke Sakai, Mika Tanabe, Takuya Mizuno","doi":"10.21873/invivo.13808","DOIUrl":"10.21873/invivo.13808","url":null,"abstract":"Background/aim: Soft tissue sarcoma (STS) is a mesenchymal tumor affecting multiple organs in dogs. Previous studies identified activation of the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (PKB, AKT) pathway in canine STS cell lines and clinical samples, but the underlying mechanism remains unclear. This study investigated PTEN loss, PIK3CA mutation, and EGFR over-expression as potential drivers of PI3K/AKT pathway activation in STS.Materials and methods: We analyzed 36 canine STS samples. PTEN and EGFR expression were evaluated using immunohistochemistry, while PIK3CA and EGFR mutations were assessed through DNA sequencing.Results: PTEN was expressed in all analyzed samples, with no evidence of loss. Weak PTEN expression was observed in 12 (33.3%) samples, while 24 (66.7%) showed normal expression. DNA sequencing of PIK3CA revealed a single point mutation (c.554 A>C, H554P) in one case, but no hotspot mutations were identified. High EGFR expression was significantly correlated with elevated phospho-AKT levels (p<0.0001). Immunolabelling indicated that 30 samples (83.3%) were EGFR-positive, and 27 of these also showed positive phospho-AKT labeling. Accordingly, one missense point mutation in exon 21 of EGFR (E868K) was identified in one of 12 samples.Conclusion: EGFR over-expression, rather than PTEN loss or PIK3CA mutations, may contribute to PI3K/AKT pathway dysregulation in canine STS. Further studies with larger sample sizes and additional validation techniques are necessary to confirm these findings.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"110-119"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of Brain Development in Children With Congenital Diaphragmatic Hernia - an Automated Brain Segmentation Approach. 先天性膈疝儿童脑发育评估——一种自动脑分割方法。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13828

Sherif A Mohamed, Larissa Götz, Victor Saase, Julia Elrod, Jonathan Endlein, Meike Weis, Eva Neumaier-Probst

{"title":"Assessment of Brain Development in Children With Congenital Diaphragmatic Hernia - an Automated Brain Segmentation Approach.","authors":"Sherif A Mohamed, Larissa Götz, Victor Saase, Julia Elrod, Jonathan Endlein, Meike Weis, Eva Neumaier-Probst","doi":"10.21873/invivo.13828","DOIUrl":"10.21873/invivo.13828","url":null,"abstract":"Background/aim: Congenital diaphragmatic hernia (CDH) is a critical condition affecting newborns, which often results in long-term morbidities, including neurodevelopmental delays, which affect cognitive, motor, and behavioral functions. These delays are believed to stem from prenatal and postnatal factors, such as impaired lung development and chronic hypoxia, which disrupt normal brain growth. Understanding the underlying mechanisms of these neurodevelopmental impairments is crucial for improving prognosis and patient outcomes, particularly as advances in treatments like ECMO have increased survival rates but also pose additional risks for neurodevelopment. This study aimed to evaluate brain development in 2-year-old children who underwent CDH repair, with and without ECMO, compared to healthy controls using an MRI-based automated segmentation approach.Patients and methods: The study included 31 children with CDH, of which 10 received ECMO therapy, and a control group of 31 healthy children. MRI-examinations were performed using a 3-T system. MRI data were processed using the CerebroMatic toolbox and SPM12 software to measure cerebrospinal fluid (CSF), gray matter (GM), white matter (WM), and cortical thickness (CT).Results: Patients with CDH showed significantly increased volumes of CSF (p=0.009), GM (p=0.02), and total intracranial volume (TIV) (p=0.01), compared to healthy controls. ECMO-treated patients had significantly increased GM (p=0.01) and CSF (p=0.005) volumes in comparison to healthy controls. CT was significantly higher in CDH patients regardless of ECMO therapy, indicating potential maturational deficits.Conclusion: The study reveals neurodevelopmental differences in children with CDH, particularly in those requiring ECMO therapy. Increased CT, GM, and CSF volumes suggest complex neurodevelopmental challenges.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"302-310"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Hypnotics, Accidents, and Injuries: A Study Based on the Adverse Drug Event Reporting Database in Japan. 催眠药、事故和伤害之间的关系：基于日本不良药物事件报告数据库的研究。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13846

Rintaro Sogawa, Masakazu Hatano, Fumi Nishimura, Junya Nishi, Ayaka Matsuoka, Kota Shinada, Haruna Yamada, Hiroshi Tateishi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe

{"title":"Association Between Hypnotics, Accidents, and Injuries: A Study Based on the Adverse Drug Event Reporting Database in Japan.","authors":"Rintaro Sogawa, Masakazu Hatano, Fumi Nishimura, Junya Nishi, Ayaka Matsuoka, Kota Shinada, Haruna Yamada, Hiroshi Tateishi, Yoshito Mizoguchi, Akira Monji, Chisato Shimanoe","doi":"10.21873/invivo.13846","DOIUrl":"10.21873/invivo.13846","url":null,"abstract":"Background/aim: The use of hypnotic drugs can lead to accidents and injuries. However, few reports have shown their association with these events after adjusting for many concomitant medications. This study aimed to determine whether the use of hypnotic drugs was associated with accidents and injuries.Patients and methods: Using the Japanese Adverse Event Reporting Database, 772,387 reports published between September 2023 and April 2004 were analyzed. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) for accidents and injuries associated with each hypnotic drug were calculated after adjusting for potential confounders.Results: Of the total, 12,484 reports indicated association of hypnotic drugs with accidents and injuries. The use of each hypnotic drug was associated with accidents, injuries, and other adverse events. However, a multivariate analysis adjusted for age, sex, reporting year, and concomitant medications showed a considerable decrease in ROR for melatonin receptor agonists (adjusted ROR=1.26; 95%CI=1.03-1.55) and dual orexin receptor antagonists (DORAs) (adjusted ROR=1.04; 95%CI=0.86-1.25). Particularly in DORAs, a loss of signal for accidents and injuries was observed.Conclusion: The risk of accidents and injuries may vary with hypnotic drug use; however, DORAs may be less frequently associated with these events. The results of this study provide useful information for the selection of hypnotic drugs.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"433-439"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mutations of the CEACAM5 Gene PELPK Motif in Patients With Appendiceal or Colorectal Adenocarcinoma. 阑尾或结直肠腺癌患者CEACAM5基因PELPK基序突变

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13806

Adam Thomas Cristaudo, Shoma Barat, Nima Ahmadi, David Morris

{"title":"Mutations of the CEACAM5 Gene PELPK Motif in Patients With Appendiceal or Colorectal Adenocarcinoma.","authors":"Adam Thomas Cristaudo, Shoma Barat, Nima Ahmadi, David Morris","doi":"10.21873/invivo.13806","DOIUrl":"10.21873/invivo.13806","url":null,"abstract":"Background/aim: The study examines whether DNA level mutations in the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) gene Pro-Glu-Leu-Pro-Lys (PELPK) motif differ between patients with appendiceal or colorectal adenocarcinoma. Significant differences between these two groups in correlation with development of metachronous liver metastases could help in the development of targeted therapies and preventative treatment approaches.Patients and methods: This retrospective comparative trial analysed 18 patients, 9 with appendiceal adenocarcinoma and 9 with colorectal adenocarcinoma. Genetic sequencing was conducted to detect mutations in the CEACAM5 gene PELPK motif. Data collection spanned from 2016 to 2022, with analysis completed in 2024 at a single tertiary care referral centre, where all participants underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.Results: No DNA mutations were detected in the CEACAM5 gene PELPK motif in either the study groups. Despite this, significant (but not unexpected) differences were observed between the two groups regarding operative time, peritoneal cancer index, and length of hospital stay (p=0.031, 0.001, and 0.005, respectively). Patients with colorectal adenocarcinoma also had significantly more synchronous liver metastases present at time of their peritonectomies (p=0.029).Conclusion: The absence of DNA level mutations in the CEACAM5 gene PELPK motif underscores the need for further research at the mRNA and protein levels to better understand the biological distinctions between these two groups. Future studies should focus on exploring alternative molecular pathways that may contribute to the differing clinical profiles of appendiceal and colorectal adenocarcinoma patients.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"96-101"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With KIT Exon 11 W557_K558 Deletion. 低剂量伊马替尼对KIT外显子11 W557_K558缺失的胃肠道间质瘤患者的疗效

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13857

Hirotaka Suto, Miyuki Kawamura, Mitsunori Morita, Hideki Sakai, Takuma Onoe, Kyoko Ikeuchi, Kazuyoshi Kajimoto, Koji Matsumoto

{"title":"Low-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With KIT Exon 11 W557_K558 Deletion.","authors":"Hirotaka Suto, Miyuki Kawamura, Mitsunori Morita, Hideki Sakai, Takuma Onoe, Kyoko Ikeuchi, Kazuyoshi Kajimoto, Koji Matsumoto","doi":"10.21873/invivo.13857","DOIUrl":"10.21873/invivo.13857","url":null,"abstract":"Background/aim: Gastrointestinal stromal tumors (GISTs) are rare cancers originating from Cajal's stromal cells in the gastrointestinal tract. The most common driver mutation in these cancers is the KIT mutation. This report presents a case of response to low-dose imatinib in a patient with GIST harboring KIT exon 11 W557_K558 deletion.Case report: In June 2023, an 82-year-old male developed perineal pain. Computed tomography (CT) imaging revealed a mass measuring >9 cm, extending from the rectum to the prostate. Submucosal tumor biopsy revealed a tumor with CD117-positive and DOG1-positive spindle-shaped cells leading to a diagnosis of GIST. c-Kit gene mutation analysis detected a W557_K558 deletion in exon 11. Treatment with imatinib (400 mg/day) was initiated in late October 2023 to preserve organ function; the dose was reduced to 300 mg/day after 5 days of treatment and further reduced to 200 mg/day after 10 days, with continued treatment at this dose. The CT performed in January, April, and June 2024 showed that the rectal GIST had shrunk. The blood imatinib concentration remained at approximately 650 ng/ml from January to March 2024 and decreased to 391 ng/ml in May 2024.Conclusion: The response rate of GISTs to imatinib is influenced by genetic mutations. GIST with KIT exon 11 W557_K558 deletion is associated with a high risk of recurrence. In vitro data showed that low-dose imatinib was effective in such cases. Low-dose imatinib is a treatment option for patients with GIST harboring KIT exon 11 W557_K558 deletion who are intolerant to high-dose imatinib.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"532-538"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic Syndrome and Somatic Composition: A Large Cross-sectional Analysis. 代谢综合征和躯体组成：一个大的横断面分析。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13839

Masahiro Matsui, Akira Fukuda, Saori Onishi, Kosuke Ushiro, Tomohiro Nishikawa, Akira Asai, Soo Ki Kim, Hiroki Nishikawa

{"title":"Metabolic Syndrome and Somatic Composition: A Large Cross-sectional Analysis.","authors":"Masahiro Matsui, Akira Fukuda, Saori Onishi, Kosuke Ushiro, Tomohiro Nishikawa, Akira Asai, Soo Ki Kim, Hiroki Nishikawa","doi":"10.21873/invivo.13839","DOIUrl":"10.21873/invivo.13839","url":null,"abstract":"Background/aim: To elucidate the relationship between metabolic syndrome (Mets) and somatic composition [fat mass, fat-free (FF) mass, and fat to fat-free (F-FF) ratio] among health checkup recipients (7,776 males and 10,121 females).Patients and methods: We classified study subjects into four types considering Japanese criteria for Mets; Type A is for males with waist circumference (WC) <85 cm and females with WC <90 cm, Type B is for males with WC ≥85 cm and females with WC ≥90 cm, but without any metabolic abnormalities, Type C is for males with WC ≥85 cm and females with WC ≥90 cm and one metabolic disorder (pre-Mets), and Type D is Mets. We compared baseline characteristics among types of A, B, C, and D.Results: F index, FF index, and F-FF ratio showed an increasing trend with increasing risk factors for Mets in both sexes.Conclusion: This study demonstrates a clear correlation between somatic composition and the severity of metabolic syndrome (Mets). As Mets risk factors increase, fat mass, fat-free mass, and the fat-to-fat-free ratio also rise, indicating that body composition shifts with disease progression. These findings emphasize the need for early intervention, such as exercise and diet, to manage somatic composition imbalances and reduce complications like insulin resistance.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"381-389"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preclinical Assessment of Safety and Efficacy of Deferoxamine (DFO)-pretreated Feline Adipose Mesenchymal Stem Cells. 去铁胺（DFO）预处理猫脂肪间充质干细胞安全性和有效性的临床前评估。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13825

Hailong Teng, Minkyung Cho, Zhiqiang Ma, Xinpeng Ji, Shiyu Jin, Yuze Zhou, Meifu Xuan, Hyun-A Seong, Xiangzi Li, Seong-Ho Choi, Qiang Li

{"title":"Preclinical Assessment of Safety and Efficacy of Deferoxamine (DFO)-pretreated Feline Adipose Mesenchymal Stem Cells.","authors":"Hailong Teng, Minkyung Cho, Zhiqiang Ma, Xinpeng Ji, Shiyu Jin, Yuze Zhou, Meifu Xuan, Hyun-A Seong, Xiangzi Li, Seong-Ho Choi, Qiang Li","doi":"10.21873/invivo.13825","DOIUrl":"10.21873/invivo.13825","url":null,"abstract":"Background/aim: This study aimed to investigate the safety and efficacy of deferoxamine (DFO) pretreated feline adipose tissue derived mesenchymal stem cells (fATMSCs) for the treatment of inflammatory disorders.Materials and methods: fATMSCs were isolated from feline adipose tissue and characterized using flow cytometry for surface marker expression and differentiation assays for adipogenic, osteogenic, and chondrogenic lineages. Different concentrations of DFO were used to evaluate its impact on fATMSC activity. The therapeutic potential of these preconditioned cells was validated using a mouse model of acute lung injury (ALI) by LPS injection. Comprehensive evaluations, including clinical, hematological, and radiological assessments, were conducted before and after intravenous injection of preconditioned cells in three feline subjects.Results: 25 μM DFO pretreatment significantly up-regulated immunomodulatory genes (Tgfb, Hgf, and Tsg-6) in fATMSCs. In the mouse ALI model, DFO-pretreated fATMSCs exhibited enhanced anti-inflammatory effects, reducing inflammatory cytokines (Tnfa, Il1b, Il6). Clinical safety assessment in felines showed no immediate adverse effects, structural alterations, or tumorigenesis.Conclusion: Utilizing a mouse model of acute lung injury, we demonstrated the potential of DFO-pretreated fATMSCs as a safe and effective therapeutic approach for inflammatory disorders.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"267-279"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Appendiceal Neuroendocrine Tumor: Clinicopathologic Characteristics of Six Cases and Review of the Literature. 阑尾神经内分泌肿瘤6例临床病理特点及文献复习。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13860

Yeseul Kim, You-Na Sung, Anna Therese Datuin, Inho Jang, Jongmin Sim

{"title":"Appendiceal Neuroendocrine Tumor: Clinicopathologic Characteristics of Six Cases and Review of the Literature.","authors":"Yeseul Kim, You-Na Sung, Anna Therese Datuin, Inho Jang, Jongmin Sim","doi":"10.21873/invivo.13860","DOIUrl":"10.21873/invivo.13860","url":null,"abstract":"Background/aim: Appendiceal neuroendocrine tumors (ANETs) are the most prevalent type of appendiceal neoplasm and the fifth most common neuroendocrine tumor in the gastrointestinal tract. In this study, we described the clinicopathological features of patients with ANET.Patients and methods: We reviewed the clinicopathological findings and histopathological reports of six patients diagnosed with ANET between January 2014 and December 2023 at Korea University Medical Center, Anam Hospital.Results: Six cases, comprising three males and three females, were diagnosed during procedures for lower abdominal pain or other medical reasons. Most tumors were less than 1 cm in size and located at the tip of the appendix. One patient had a large tumor (4.1 cm) with lymph node metastasis. Four tumors extended to the muscularis propria, whereas two infiltrated the subserosal soft tissue. The tumor cells exhibited a typical trabecular and nested pattern with monotonous round or oval nuclei. All patients had a mitotic count of less than 2 per 10 high-power fields and a Ki-67 labeling index of less than 1%, classifying them as having G1 well-differentiated tumors. Immunohistochemical staining showed that all cases were positive for CD56 and synaptophysin, and four were positive for chromogranin A. No recurrence or distant metastasis was observed during follow-up.Conclusion: ANETs are relatively uncommon and mostly benign in terms of prognosis. Because of their malignant potential, meticulous examination of appendectomy specimens is warranted to identify the presence of ANETs.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"559-565"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database. 使用日本不良药物事件报告（JADER）数据库对尼达尼布相关的肝毒性和胃肠道不良事件进行歧化分析。

IF 1.8 4区医学

In vivo Pub Date : 2025-01-01 DOI: 10.21873/invivo.13841

Masaki Fujiwara, Hiroaki Ikesue, Kenta Yamaoka, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu

{"title":"Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database.","authors":"Masaki Fujiwara, Hiroaki Ikesue, Kenta Yamaoka, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu","doi":"10.21873/invivo.13841","DOIUrl":"10.21873/invivo.13841","url":null,"abstract":"Background/aim: Nintedanib may cause adverse events such as elevated liver enzyme levels, diarrhea, and decreased appetite. These adverse events should be managed appropriately as they affect the quality of life of patients. This study has aimed to analyze patient characteristics and time-to-onset of adverse events caused by nintedanib using the Japanese Adverse Drug Event Report (JADER) database.Patients and methods: Data from April 2004 to June 2023 were extracted from the JADER database and the patient characteristics of nintedanib administration were evaluated using reported odds ratio (ROR) and 95% confidence interval (95%CI). The data were analyzed for time-to-onset and patient characteristics such as age, sex, body mass index (BMI), and the presence or absence of prednisolone.Results: The JADER database included 1,419 adverse event reports in which nintedanib was suspected. The number (%) and ROR of adverse events known to occur with the use of nintedanib were 72 (5.07%) cases of decreased appetite [ROR=7.09 (95%CI=5.59-8.99)], and 79 (5.57%) cases of diarrhea [ROR=6.52 (5.19-8.18)]. The median days until onset were 19.5 (IQR=6.25-50.5) days for hepatotoxicity, 119.5 (IQR=24.5-258.5) days for diarrhea, and 131.5 (IQR=20.5-334.5) days for decreased appetite.Conclusion: Nintedanib is more likely to cause elevated liver enzyme levels, diarrhea, and decreased appetite than other drugs. These events occurred within approximately 3-4 months. The concomitant use of prednisolone may also be associated with gastrointestinal hemorrhage.","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 1","pages":"396-403"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vivo最新文献